Curtis Bazemore, MD
Family Medicine · North Las Vegas, NVNPI 1477619831
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 111 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 23 manufacturers, the largest accounting for just 22.3% — the pattern of someone who eats at a lot of different presentations.
Across 111 payments — averaging $16.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$418
- AstraZeneca$252
- Genentech USA, Inc.$217
- Amgen$164
- Pfizer$142
- Biohaven Pharmaceutical Holding Company Ltd.$117
- plus $564 from 17 others
Across 22 payments — averaging $2586.36 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Shire North American Group Inc$48K
- Takeda Pharmaceuticals U.S.A., Inc.$9K
What the payments were for
- Food & beverage$1,874100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,874 in reported general payments places this provider in the 75th percentile of 902 family medicine providers in Nevada.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 56 | $45,151 |
| JardianceEmpagliflozin | 22 | $18,181 |
| JanuviaSitagliptin Phosphate | 19 | $16,699 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $6,726 |
| Celecoxib | 89 | $3,556 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 141 | $3,149 |
| Gabapentin | 137 | $2,376 |
| BreynaBudesonide/Formoterol Fumarate | 11 | $1,954 |
| Diclofenac Sodium | 35 | $1,806 |
| Levothyroxine Sodium | 144 | $1,555 |
| Nifedipine ErNifedipine | 38 | $1,228 |
| Wixela InhubFluticasone Propion/Salmeterol | 31 | $1,223 |
| Quetiapine Fumarate | 27 | $1,147 |
| Atorvastatin Calcium | 218 | $1,127 |
| Ventolin HfaAlbuterol Sulfate | 15 | $953 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $142 | $45,15156 claims |
| Boehringer IngelheimJardiance | $47 | $18,18122 claims |
| GSKBreo Ellipta | $15 | $6,72611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 902 family medicine providers in Nevada.
Other family medicine in North Las Vegas
- Naz WahabLas Vegas$563K
- Jerry CadeLas Vegas$180K
- Nilesh GokalLas Vegas$75K
- Bayo Curry-WinchellReno$74K
- Warren MagnusLas Vegas$70K
- Catherine McCarthyReno$68K
- Kimberly AdamsLas Vegas$51K
- Badi EghterafiHenderson$38K
- Francisco DofelizReno$30K
- Mandeep GillLas Vegas$24K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.